Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 700

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 2
Chunk 700
---
. Yanez will be entitled to severance compensation
in the form of salary continuation for a period of three months (subject to Ms. Yanez executing and delivering a customary general release
in favor of the company). “Cause” is defined in the agreement to include dishonesty, misappropriation, willful misconduct,
breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Ms.
Yanez’s compensation or duties and level of responsibility. The employment agreement also contains customary confidentiality and
invention-assignment covenants to which Ms. Yanez is subject. The employment agreement also contains customary confidentiality
and invention-assignment covenants to which Ms. Yanez is subject.

Christopher
Chapman, MD

On
August 8, 2024, the Company was made aware of the passing of its Chairman and Chief Executive Officer, Dr. Christopher Chapman. There were no clauses in his employment agreement that had an effect on the Company.

Nathen
Fuentes, CPA

On
June 18, 2024, we entered into a Confidential Separation and Mutual General Release Agreement (the “Separation Agreement”)
with Nathen Fuentes whereby we mutually agreed that Mr. Fuentes’ employment as our Chief Financial Officer ended as of June 18,
2024. Provided that Mr. Fuentes did not revoke the acceptance of the Separation Agreement and complied with the terms therein, we would
pay Mr. Fuentes from the date thereof an aggregate of $62,500 in equal installments over three months in accordance with our regular
payroll schedule. The amount was paid in accordance with the agreements and no amounts are still outstanding as of December 31, 2024.

62

Grants
of Plan-Based Awards in 2024

    Estimated
    Future Payouts Under Non-Equity Incentive Plan Awards  
    Estimated
    Future Payouts Under Equity Incentive 
    Plan Awards  
    All Other
    Stock Awards: Number of Shares of Stocks  
    All Other
    Option Awards: Number of Securities Underlying   
    Exercise or
    Base Price of Option  
    Closing stock
    price on Award  
    Grant Date
    Fair Value of Stock and Option  

    Grant  
    Threshold  
    Target  
    Maximum  
    Threshold  
    Target  
    Maximum  
    or